Artiva Biotherapeutics (NASDAQ:ARTV) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report published on Wednesday,Benzinga reports. Needham & Company LLC currently has a $23.00 price target on the stock.

A number of other research firms have also recently weighed in on ARTV. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, August 30th. TD Cowen initiated coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a “buy” rating for the company. Jefferies Financial Group assumed coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Cantor Fitzgerald began coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $21.25.

Artiva Biotherapeutics Trading Down 10.5 %

Shares of ARTV opened at $11.70 on Wednesday. Artiva Biotherapeutics has a 52 week low of $9.68 and a 52 week high of $17.31. The business has a 50-day moving average of $12.59.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Thursday, August 29th. The company reported ($19.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($18.03). On average, research analysts predict that Artiva Biotherapeutics will post -4.6 EPS for the current fiscal year.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently made changes to their positions in the company. MetLife Investment Management LLC acquired a new position in Artiva Biotherapeutics in the 3rd quarter valued at $135,000. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth $42,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $623,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.